ABSTRACT
BACKGROUND Ultra-high field MR imaging offers marked gains in signal-to-noise ratio, spatial resolution, and contrast which translate to improved sensitivity for pathology and anatomy. These benefits are particularly relevant for the neonatal brain, as it is rapidly developing and sensitive to injury. However, experience of imaging neonates at 7T has been limited due to regulatory, safety, and practical considerations.
PURPOSE To establish a program for safely acquiring high resolution and contrast brain images from neonates on a 7T system.
STUDY TYPE Prospective case series.
POPULATION Images were safely acquired from 35 neonates on 44 occasions (median age 39+6 postmenstrual weeks, range 33+4 to 52+6; median body weight 2.93kg, range 1.57to 5.3kg) over a median of 49 mins 30 sec.
FIELD STRENGTH/SEQUENCE 7T, acquired sequences included T2 weighted (TSE), Actual Flip angle Imaging, functional MRI (BOLD EPI), susceptibility weighted imaging, and MR spectroscopy (STEAM).
ASSESSMENT Peripheral body temperature, physiological measures (heart rate, oxygen saturations). Review of acquired images by Neonatal Neuroradiologists for visual identification of anatomy and pathology, and by radiographer and researcher for assessment of image quality.
STATISTICAL TESTS Two tailed paired t-test, P<0.05 was considered statistically significant.
RESULTS There was no significant difference between temperature before and after scanning (p=0.76). Image quality assessment compared favourably to state-of-the-art 3T acquisitions. Anatomical imaging demonstrated excellent sensitivity to structures which are typically hard to visualise at lower field strengths including the hippocampus, cerebellum, and vasculature. The potential of 7T imaging is highlighted using contrast mechanisms which are enhanced at ultra-high field including susceptibility weighted imaging, functional MRI, and MR spectroscopy.
DATA CONCLUSION We demonstrate safety and feasibility of imaging vulnerable neonates at ultra-high field. Our preliminary imaging suggests ultra-high field has untapped potential to provide important new insights into brain development and pathological processes during this critical phase of early life.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was supported a project grant awarded by Action Medical Research [GN2728]. TA is also supported by an MRC Clinician Scientist Fellowship [MR/P008712/1] and Transition Support Award [MR/V036874/1]. PC, AT, JOM, MAR, ADE and TA received support from the Medical Research Council Centre for Neurodevelopmental Disorders, Kings College London [MR/N026063/1]. LCG received support by project PID2021-129022OA-I00, funded by MCIN / AEI / 10.13039/501100011033 / FEDER, EU. The authors also acknowledge support in part from the Wellcome Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at Kings College London [WT 203148/Z/16/Z].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NHS Health Research Authority Ethics committee of London - City & East gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
